NGM is built on a straightforward central premise: create an environment that allows drug discovery research to thrive by focusing on powerful human biology unconstrained by therapeutic area or technology approach.

NGM120 is an antibody designed to bind to the receptor (known as GFRAL) for GDF15. This binding blocks the interaction of GDF15 with GFRAL, which, in turn, inhibits the activity of GDF15, potentially alleviating HG symptoms. NGM120 has been generally well-tolerated in over 140 participants (non-pregnant) treated in clinical trials to date.

2025年2月24日 · About NGM Bio. NGM Biopharmaceuticals, Inc. (NGM Bio), a wholly owned subsidiary of NGM Bio Holdings, Inc., a privately held biotechnology company, is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. NGM Bio’s biology-centric drug discovery approach aims to ...

SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...

2024年7月17日 · NGM Bio将利用融资收益启动一项计划中的aldafermin（一种工程化FGF19类似物）的注册试验，用于治疗PSC（ 原发性硬化性胆管炎 ），并完成一项计划的NGM120（一种GDF15/GFRAL抗体）治疗HG（ ...

2024年7月17日 · NGM Bio将使用A系列融资的收益启动计划的注册试验，用于治疗PSC的工程FGF19类似物aldafermin，并完成计划的GDF15/GFRAL拮抗剂NGM120的2期试验，用于治疗HG。 Both trials are expected to begin in the fourth quarter of 2024.

2025年2月4日 · At NGM, every team member plays a vital role in furthering our goals and advancing our mission to deliver life-changing medicines for patients. We are independent-spirited while also team-oriented. We work collaboratively and fluidly — with open doors and without egos.

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today shared positive, comprehensive results from its Phase 2b ALPINE 4 trial of aldafermin, an engineered FGF19 analog produc...

We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move biologic drug candidates rapidly into proof-of-concept clinical studies. Our mission is to translate complex, powerful biology with rigor and urgency into life-changing medicines.

2024年2月26日 · Following a year that saw a third of staff laid off and a sliding share price, NGM Bio has decided to go private as part of a $135 million buyout by VC firm The Column Group.